Quest Diagnostics Completes Acquisition of LifeLabs, Enhancing Access to Diagnostic Innovation

Go back to Quest Diagnostics Completes Acquisition of LifeLabs, Enhancing Access to Diagnostic Innovation

Evercore ISI Resumes Quest Diagnostics (DGX) at In Line

August 28, 2024 5:50 AM EDT

Evercore ISI analyst Elizabeth Anderson resumes coverage on Quest Diagnostics (NYSE: DGX) with a In Line rating and a price target of $165.00.

The analyst comments "We are resuming coverage of Quest Diagnostics following the close of the LifeLabs acquisition on August 26th . Our updated 24 estimates... More